Please wait while we load the requested 10-Q report or click the link below:
3Q16 diluted EPS of $0.31 vs. $0.08 in 3Q15, 3Q16 Adjusted EPS of $0.44 vs. $0.38 in 3Q15.
Third quarter net sales of $1.14 billion, up 3.7% year-over-year, and up 1.6% on an organic basis.
3Q16 Americas net sales increased 6.0% year-over-year, up 1.7% organic. EMEA-APAC net sales increased 0.2% year-over-year, up 1.4% organic. A description and reconciliation of GAAP to non-GAAP Adjusted EPS and net sales to organic net sales is attached.
Nine months 2016 cash flow from operating activities of $186.1 million, up 18.3% compared to prior year.
Acquired PAW BioScience Products, a manufacturer and distributor of single-use fluid handling products on July 1, 2016. Announced the acquisition of BioArra, a company focused on the sourcing, production and marketing of serum-based products used in both research and bioproduction. Also announced the acquisition of Reliable Biopharmaceutical, a manufacturer of high purity excipients and process chemicals using multi-step chemical synthesis and advanced purification.
Management reaffirms 2016 Adjusted EPS guidance and anticipates 2016 net sales at, or close to, the low end of our 2016 guidance range.
The following information was filed by Vwr Corp (VWR) on Thursday, November 3, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Vwr Corp's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Vwr Corp.